| [1] |
Prabhu PG, Lisa RB, Mary S, et al. Nested case-control study: hepatocellular carcinoma risk after hepatitis b surface antigen seroclearance. Aliment Pharmacol Ther, 2016,43: 1197-1207.
|
| [2] |
中华人民共和国国家卫生和计划生育委员会.原发性肝癌诊疗规范(2017年版).临床肝胆病杂志, 2017,33:1419-1431.
|
| [3] |
Simonetti J, Bulkow L, McMahon BJ, et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology. 2010,51:1531-1537.
|
| [4] |
Liu F, Wang XW, Chen L, et al. Systematic review with meta-analysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance. Aliment Pharmacol Ther, 2016, 43: 1253-1261.
|
| [5] |
Kuang XJ, Jia RR, Huo RR, et al. Systematic review of risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. J Viral Hepat, 2018,25:1026-1037.
|
| [6] |
Yip VS, Cheung TT, Poon RT, et al. Does hepatitis B seroconversion affect survival outcome in patients with hepatitis B related hepatocellular carcinoma? Transl Gastroenterol Hepatol, 2016,1:51.
|
| [7] |
陈骋,李灼日,周开伦,等.隐匿性乙型肝炎病毒感染在隐源性肝癌发生中的作用.中华肝胆外科杂志,2017,23:513-516.
|
| [8] |
Yip TC, Chan HL, Wong VW, et al. Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. J Hepatol, 2017, 67:902-908.
|
| [9] |
Lou C, Bai T, Bi LW, et al. Negative impact of hepatitis B surface seroclearance on prognosis of hepatitis B-related primary liver cancer. World J Clin Cases, 2018, 6: 192-199.
|
| [10] |
Ying C, Yao P, Ke-Ren S, et al. Contrast-enhanced multiple-phase imaging features of intrahepatic mass-forming cholangiocarcinoma and hepatocellular carcinoma with cirrhosis: a comparative study. Oncol Lett, 2017,14: 4213-4219.
|
| [11] |
杨可立,杨 湛,关玉娟,等.行肝癌切除术的HBsAg阳性和HBsAg阴性/抗-HBc阳性原发性肝癌患者临床特点对比分析. 临床肝胆病杂志,2015,31:907-909.
|
